Skip to main content

Table 2 Pathological findings

From: Comprehensive genomic evaluation of advanced and recurrent breast cancer patients for tailored precision treatments

 

Number of patients

Pathological type

 

   Invasive ductal carcinoma

19

   Invasive lobular carcinoma

2

   Invasive micropapillary carcinoma

1

Hormonal and HER2 status*

 

   HR(+), HER2(-)

13

   HR(-), HER2(-)

7

   HR(+), HER2(+) → HR(+), HER2(-)

1

   HR(+), HER2(-) → HR(-), HER2(-)

1

PD-L1 status†

 

   22C3 Positive

2

   Negative

1

   SP142 Positive

2

   Negative

3

  1. * ER(-) plus PgR(-) was described as HR(-). ER(+) plus PgR(+) was described as HR(+)
  2. †PD-L1 immunohistochemistry was performed for the 7 patients whose hormonal and HER2 status was HR(-) and HER2(-)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us